

g17
can

CGTCGGATCCTCTAGATGCGGCCGCCACGGGGGGAGCAGCC

TCTGG

Page ⁴⁶28: remove the third paragraph and insert therefor:

The specific double-stranded DNA sequence used in this experiment consists of

two synthetic oligonucleotides whose sequence is the following:

Oligo 5997 (SEQ ID No. 28) :

GATCCGACTTTCACCTTTTCTCTATCACTGATAGTGAGTGGTAAACTCA

Oligo 5998 (SEQ ID No. 29) :

AGCTTGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCG

Page 49: remove first paragraph and insert therefor:

The two oligonucleotides thus labelled were then hybridised in the presence of

400 mM NaCl in order to reconstitute the following double-stranded sequence TetO:

5'- GATCCGACTTTCACCTTTTCTCTATCACTGATAGTGAGTGGTAAACTCA -3'

(SEQ ID No. 28)

3'- CTAGGCTCAAAGTGAAAAGAGATAGTGACTATCACTCACCATTGAGT -5'

(SEQ ID No. 30)

REMARKS

These amendments are being made in to the instant Application in response to the Examiner's communication of July 23, 2001. In the communication, the Examiner asserted that the sequence rules were not complied with as required. In particular, the communication explained that in the Sequence Listing, Applicants did not explain the

source of genetic material set forth in the instant Application. The Examiner also believed that amendments made to on June 6, 2001 to the Specification and Figures were not proper and did not comply with 37 CFR 1.121.

In response, Applicants submit a substitute sequence listing wherein the source of genetic material described as an "artificial sequence" is described in the Sequence Listing, a CRF form of the sequence, and a Statement under 37 CFR 1.821-1.825.

Applicants also submit amendments to the instant Specification that are in the form set forth in 37 CFR 1.121, as well as substitute Figures 4 and 6 showing the changes to be made in these figures in red ink. Attached hereto is a marked-up version of the changes made to the Specification by the instant Amendment. The attached page is captioned

"Version With Markings To Show Changes Made." The amendments made to the Specification are intended merely to have the instant Specification conform to the SEQ ID numbers assigned to the various sequences in the substitute sequence listing. Thus, no new matter has been added to the instant Specification or Claims.


Fees

No fees are believed to be necessitated by the instant response. However, should this be in error, authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments.

CONCLUSION

Applicants respectfully request entry of the foregoing amendments and remarks in the file history of the instant Application. Early and favorable action on the Claims is earnestly solicited.

Respectfully submitted,



William C. Coppola
Attorney for Applicant(s)
Registration No. 41,686

AVENTIS PHARMACEUTICALS PRODUCTS, INC.
Route 202-206; Mail Stop: EMC-G1
P.O. Box 6800
Bridgewater, NJ 08807
August 7, 2001



Version With Markings To Show Changes Made

IN THE SPECIFICATION:

Page 13, second paragraph:

In a preferred embodiment, the domain capable of binding selectively a defined sequence of DNA present in the molecules of the invention is derived from the tetR or Cro proteins. It is most particularly advantageous to use the complete tetR or Cro proteins [(SEQ ID No. 21)].

TECH CENTER 1600/2900

AUG 14 2001

RECEIVED

Page 14, first paragraph:

4 or 5 leucines every 7 amino acids. This periodicity allows the localization of the leucines roughly at the same position on the α helix. The dimerization is sustained by hydrophobic interactions between the same chains of the leucine of two contiguous zipper domains (Vogt et al., Trends in Bioch. Science 14 (1989) 172). The SH2 domains can be used to form an oligomer with any transactivator or transactivating complex comprising the corresponding proline-rich peptide (Pawson et al., Current Biology 3 (1993) 434). It is also possible to use protein regions known to induce oligomerization, such as especially the C-terminal region of the p53 protein. The use of this region makes it possible to recruit selectively the p53 proteins present in a cell. A p53 region between amino acids 320-290 (SEQ ID No. 3)[, 302-360 (SEQ ID No. 33) or 302-290 (SEQ ID No. 34)] is preferably used within the framework of the invention.

Page 16, third paragraph:

The DNA binding domain and the transactivator-binding domain are generally linked to each other through an arm. This arm generally consists of a peptide which confers sufficient flexibility for the two domains of the molecules of the invention to be functional autonomously. This peptide is generally composed of uncharged amino acids, which do not interfere with the activity of the molecules of the invention, such as for example glycine, serine, tryptophan, lysine or proline. The arm generally comprises from 5 to 30 amino acids and, preferably, from 5 to 20 amino acids. Examples of peptide arms which can be used for the construction of the molecules are for example:

-GGGGSGGGGSGGGGS (SEQ ID No. 5)

-PKPSTPPGSS (SEQ ID No. [7] 6).

Page 17, first paragraph:

Sequence is CCCAAGCCCAGTACCCCCCAGGTTCTTCA (SEQ ID No. [6] 7).

Page 17: remove third paragraph and insert therefor:

This type of molecule comprises:

- a domain for binding to a transactivator consisting of a single-chain antibody, a tag peptide sequence recognized by a monoclonal antibody allowing the immunological detection of the molecule. This sequence may be for example the VSV epitope of the MNRLGK sequence (SEQ ID No. [9] 8) whose coding sequence is ATGAACCGGCTGGGCAAG (SEQ ID No. [8] 9) or the [moic] myc epitope of the sequence EQKLISEEDLN (SEQ ID No. [11] 10) whose coding sequence is GAACAAAACTCATCTCAGAAGAGGATCTGAAT (SEQ ID No. [10] 11), which is recognized by the antibody 9E10

- a peptide arm of sequence SEQ ID No. [7] 6 (Hinge) and
- a DNA-binding domain consisting of the TET or Cro protein. Preferably, ScFv is directed against a p53 protein.

Page 20, first paragraph:

Consists in a nucleic acid sequence encoding a chimeric molecule as defined above. It is advantageously a DNA, especially a cDNA, sequence. It may also be an RNA. The sequences of the invention are generally constructed by assembling, within a cloning vector, the sequences encoding the various domains according to conventional molecular biology techniques. The nucleic acid sequences of the invention can optionally be modified chemically, enzymatically or genetically, in order to generate domains which are stabilized, and/or multifunctional, and/or of reduced size, and/or with the aim of promoting their location in such or such intracellular compartment. Thus, the nucleic acid sequences of the invention may comprise sequences encoding nuclear localization peptides (NLS). In particular, it is possible to fuse the sequences of the invention with the sequence encoding SV40 virus NLS, whose peptide sequence is the following: PKKKRKV (SEQ ID No. 12 [9]) (Kalderon et al., Cell 39 (1984) 499).

Page 22, second paragraph:

As regards the minimal transcriptional promoter, it is a promoter whose activity depends on the presence of a transactivator. Because of this, in the absence of the chimeric molecule, the promoter is inactive and the gene is not or is barely expressed. On the other hand, in the presence of a chimeric molecule, the transactivator or

transactivating complex recruited makes it possible to induce the activity of the minimal promoter and thus the expression of the gene of interest. The minimal promoter generally consists of an INR or a TATA box. These components are indeed the minimum components necessary for the expression of a gene in the presence of a transactivator. The minimal promoter can be prepared from any promoter by genetic modification. By way of preferred example of a candidate promoter, there may be mentioned the promoter of the thymidine kinase gene. Advantageous results have more precisely been obtained with a minimal promoter derived from the TK promoter that comprises the TATA box of the thymidine kinase promoter [composed of nucleotides – 37 to +19 (SEQ ID No. 36). The minimal promoter can also be derived]

Page 23, first paragraph:

from human CMV. [In particular, it may consist of the fragment between nucleotides – 53 and +75 or –31 and +75 from CMV.] Any-conventional promoter can however be used such as, for example the promoter of the genes encoding chloramphenicol acetyltransferase, β -galactosidase or alternatively luciferase

Page 23, third paragraph:

Still more preferably, the minimal promoter includes the TATA box of the thymidine kinase gene promoter [consists of the –37 to +19 (SEQ ID No. 36) region of the promoter of the thymidine kinase gene].

Page 31, third paragraph:

Among the synthetic vectors developed, the cationic polymers of the polylysine, [(LKLK)_n (SEQ ID No. 30) , (LKKL)_n (SEQ ID No. 31)] (LKLK)_n (SEQ ID NO:13), (LKKL)_n (SEQ ID NO:14), poly(ethylenimine) and DEAE dextran type or alternatively the cationic lipids or lipofectants are the most advantageous. They possess the properties of condensing the ADN and of promoting its association with the cell membrane. Among the latter, there may be mentioned the lipopolyamines (lipofectamine, transfectam and the like) and various cationic or neutral lipids (DOTMA, DOGS, DOPE and the like) more recently, the concept of targeted transfection, mediated by a receptor, has been developed, which takes

Page 39, first paragraph:

1.2 Construction of the plasmid pTETop7/CAT

The plasmid pTETop7/CAT contains the following components (Figure 3):

- a regulatory sequence consisting of a sequence for interaction with the tetracycline repressor TetR composed of 7 repeated Tetop motifs (SEQ ID No. 1);
- a minimal promoter derived from the promoter of the thymidine kinase gene that includes the TATA box of the thymidine kinase gene promoter [(-37 to +19 region carrying the TATA box)];
- the sequence encoding chloramphenicol acetyltransferase (CAT) under the control of the said minimal promoter.

Page 40, first, second and third paragraphs:

promoter of the thymidine kinase gene that includes the TATA box of the thymidine kinase gene promoter [(-37 to +19 region carrying the TATA box)];

- the sequence encoding chloramphenicol acetyltransferase (CAT) under the control of the said minimal promoter.

This plasmid was constructed in the following manner: the sequence OR3 for interaction with the Cro repressor was synthesized artificially. For that, the following two oligonucleotides were synthesized:

Oligo 5533 (SEQ ID No. 15 [25]): 5'- GATCCTATACACCGCAAGGGATAA-3'

Oligo 5534 (SEQ ID No. 16 [26]): 3'-GATAGTGGCGTTCCTATTTCGA-5'

These two oligonucleotides were then hybridized in order to reconstitute the double-stranded sequence OR3 bordered by sequences allowing its oriented cloning as follows:

GATCCTATACACCGCAAGGGATAA (SEQ ID No. 15 [25])

GATAGTGGCGTTCCTATTTCGA (SEQ ID No. 16 [26])

Page 42, first and second paragraphs:

3.1. Construction of a plasmid comprising a sequence ScFv-myc-Hinge-TetR or Cro (Figures 5A and 6) encoding the anti-p53 ScFv was first cloned into a plasmid of the pUC19 type. The sequence encoding the VsV epitope (SEQ ID No. 8 [6]) or the myc epitope (SEQ ID No. 10 [8]) is inserted downstream of the fragment (Figure 6).

The sequence encoding the TetR and Cro proteins were then obtained as follows:

- The sequence encoding TetR was obtained by amplification from a template plasmid carrying the TetR sequence by means of the following oligonucleotides:

Oligo 5474 (SEQ ID No. 17 [13]) :

Page 43, first, second and third paragraphs:

GGCTCTAGACCCAAGCCCAGTACCCCCCAGGTTCTTCAACGCGTGGA
TCCATGTCCAGATTAGATAAAAGTAAAG

Oligo 5475 (SEQ ID No. 18 [14]):

CGTACGGAATTCGGGCCCTTACTCGAGGGACCCACTTTCACATTTAAG
TTG

These oligonucleotides also provide the sequence encoding the Hinge peptide arm linking the two functional domains of the molecules.

The amplified fragment therefore contains the sequence encoding the peptide arm and the domain for binding to the tetR DNA. This fragment was cloned into the XbaI-EcoRI sites of the plasmid obtained above in order to generate a plasmid containing the sequence encoding the molecule ScFv-myc-Hinge-TetR (Figure 6).

The sequence encoding Cro was obtained by amplification on a DNA template of the lambda bacteriophage by means of the following oligonucleotides:

Oligo 5531 (SEQ ID No. 19 [15]) :

GGCTCTAGACCCAAGCCCAGTACCCCCCAGGTTCTTCAACGCGTGGA
TCCATGGAACAACGCATAACCCTGAAAG

Oligo 5532 (SEQ ID No. 20 [16])

CGTACGGAATTCGGGCCCTTACTCGAGTGCTGTTGTTTTTTGTTACTCGG

Page 45, first paragraph:

The cDNA encoding the oligomerizing region of the p53 protein (SEQ ID No. 3) was obtained by PCR amplification on a plasmid carrying the cDNA of the human wild-type p52 with the aid of the following oligonucleotides:

Oligo 5535 (SEQ ID No. 21 [17]) :

CAGGCCATGGCATGAAGAAACCACTGGATGGAGAA

(the underlined part represents an NcoI site)

Oligo 5536 (SEQ ID No. 22 [18]) :

CGTCGGATCCTCTAGATGCGGCCGCGTCTGAGTCAGGCCCTTC

(Underlined part : BamHI site; double underlined: XbaI site: bold: NotI site).

Page 46, second paragraph:

4.5. The plasmids tetR or Cro-p53 320/393 (Figure 5D) or tetR or Cro-Hinge-p53 320/393 (Figure 5E) were obtained by cloning fragments amplified by PCR on a plasmid carrying the cDNA for the wild-type human p53 with the aid of the oligos 5537/5539 or 5538/5539 digested with XhoI/EcoRI into the plasmids described in 3.1, previously digested with XhoI/EcoRI.

Oligo 5537 (SEQ ID No. 23 [19]) :

CAGGCTCGAGAAGAAACCACTGGATGGAGAA

Oligo 5538 (SEQ ID No. 24 [20]) :

CAGGCTCGAGCCCAAGCCCAGTACCCCCCAGGTTCTTCAAAG
AAACCACTGGATGGAGAA

Oligo 5539 (SEQ ID No. 25 [21]) :

GGTCGAATTCGGGGCCCTCAGTCTGAGTCAGGCCCTTC

Page 47, first paragraph:

Using a plasmid carrying the cDNA for the human wild-type p53 with the aid of the oligos 5661/5662 and then digested with NcoI/NotI, NcoI/XbaI, NcoI/BamHI into the plasmids described in 3.1., predigested with NcoI/NotI, NcoI/XbaI or NcoI/BamHI.

Oligo 5661 (SEQ ID No. 26 [22]) :

CAGGCCATGGAGGAGCCGCAGTCAGATCC

Oligo 5662 (SEQ ID No. 27 [23]) :

CGTCGGATCCTCTAGATGCGGCCGCCACGGGGGGGAGCAGCC
TCTGG

Page 28, third paragraph:

The specific double-stranded DNA sequence used in this experiment consists of two synthetic oligonucleotides whose sequence is the following:

Oligo 5997 (SEQ ID No. 28 [27]) :

GATCCGACTTTCACCTTTTCTCTATCACTGATAGTGAGTGGTAAACTCA

Oligo 5998 (SEQ ID No. 29 [28]) :

AGCTTGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCG

Page 49, first paragraph:

The two oligonucleotides thus labelled were then hybridised in the presence of 400 mM NaCl in order to reconstitute the following double-stranded sequence TetO [(SEQ ID No. 26)] :

5'- GATCCGACTTTCACCTTTTCTCTATCACTGATAGTGAGTGGTAAACTCA -3'

(SEQ ID No. 28)

[GATCGACTTTCACCTTTTCTCTATCACTGATAGTGAGTGGTAAACTCA]

3'- CTAGGCTCAAAGTGAAAAGAGATAGTGACTATCACTCACCATTGAGT -5'

(SEQ ID No. 30)

[CTAGGCTCAAAGTGAAAAGAGATAGTGACTATCACTCACCATTGAGT (SEQ
ID No. 35)]